News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
568,876 Results
Type
Article (42401)
Company Profile (84)
Press Release (526391)
Multimedia
Podcasts (50)
Webinars (11)
Section
Business (158653)
Career Advice (2474)
Deals (28742)
Drug Delivery (98)
Drug Development (76190)
Employer Resources (142)
FDA (14148)
Job Trends (12643)
News (282958)
Policy (27950)
Tag
2024 BioCapital Digital (2)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (2)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (1)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (6)
2024 Biotech Beach Digital (2)
2024 Biotech Beach Standard (2)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (4)
2026 BioCapital Elite (1)
2026 BioMidwest Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
2026 Pharm Country Standard (1)
Academia (2649)
Academic (1)
Accelerated approval (5)
Adcomms (26)
Allergies (84)
Alliances (40314)
ALS (93)
Alzheimer's disease (1420)
Antibody-drug conjugate (ADC) (129)
Approvals (14139)
Artificial intelligence (240)
Autoimmune disease (23)
Automation (16)
Bankruptcy (315)
Best Places to Work (10283)
BIOSECURE Act (16)
Biosimilars (92)
Biotechnology (67)
Bladder cancer (79)
Brain cancer (28)
Breast cancer (270)
Cancer (2195)
Cardiovascular disease (189)
Career advice (2081)
Career pathing (32)
CAR-T (153)
Cell therapy (410)
Cervical cancer (17)
Clinical research (62178)
Collaboration (740)
Compensation (292)
Complete response letters (23)
COVID-19 (2554)
CRISPR (42)
C-suite (247)
Cystic fibrosis (91)
Data (2134)
Decentralized trials (2)
Denatured (8)
Depression (52)
Diabetes (262)
Diagnostics (5845)
Digital health (14)
Diversity (4)
Diversity, equity & inclusion (38)
Drug discovery (116)
Drug pricing (94)
Drug shortages (24)
Duchenne muscular dystrophy (92)
Earnings (57680)
Editorial (38)
Employer branding (19)
Employer resources (129)
Events (78533)
Executive appointments (712)
FDA (15307)
Featured Employer (23)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (683)
Gene editing (103)
Generative AI (21)
Gene therapy (310)
GLP-1 (719)
Government (4276)
Grass and pollen (5)
Guidances (51)
Healthcare (16659)
Huntington's disease (25)
IgA nephropathy (30)
Immunology and inflammation (128)
Indications (29)
Infectious disease (2703)
Inflammatory bowel disease (134)
Inflation Reduction Act (8)
Influenza (53)
Intellectual property (91)
Interviews (527)
IPO (12978)
IRA (41)
Job creations (2744)
Job search strategy (1706)
Kidney cancer (11)
Labor market (19)
Layoffs (447)
Leadership (22)
Legal (5926)
Liver cancer (78)
Lung cancer (323)
Lymphoma (147)
Machine learning (6)
Management (51)
Manufacturing (260)
MASH (73)
Medical device (11070)
Medtech (11074)
Mergers & acquisitions (16246)
Metabolic disorders (677)
Multiple sclerosis (79)
NASH (23)
Neurodegenerative disease (103)
Neuropsychiatric disorders (31)
Neuroscience (1973)
NextGen: Class of 2025 (5784)
Non-profit (4160)
Northern California (2241)
Now hiring (31)
Obesity (356)
Opinion (217)
Ovarian cancer (73)
Pain (87)
Pancreatic cancer (81)
Parkinson's disease (146)
Partnered (18)
Patents (220)
Patient recruitment (105)
Peanut (45)
People (52037)
Pharmaceutical (23)
Pharmacy benefit managers (11)
Phase I (18923)
Phase II (27360)
Phase III (21071)
Pipeline (1152)
Policy (135)
Postmarket research (2388)
Preclinical (7786)
Press Release (60)
Prostate cancer (103)
Psychedelics (38)
Radiopharmaceuticals (219)
Rare diseases (386)
Real estate (4431)
Recruiting (56)
Regulatory (19805)
Reports (25)
Research institute (2256)
Resumes & cover letters (363)
Rett syndrome (5)
RNA editing (4)
RSV (42)
Schizophrenia (75)
Series A (122)
Series B (76)
Service/supplier (4)
Sickle cell disease (56)
Southern California (1963)
Special edition (10)
Spinal muscular atrophy (149)
Sponsored (28)
Startups (2927)
State (2)
Stomach cancer (15)
Supply chain (61)
Tariffs (32)
The Weekly (41)
United States (19550)
Vaccines (680)
Venture capitalists (32)
Weight loss (240)
Women's health (26)
Worklife (16)
Date
Today (182)
Last 7 days (773)
Last 30 days (2412)
Last 365 days (29413)
2025 (9344)
2024 (31489)
2023 (35244)
2022 (45853)
2021 (49268)
2020 (47877)
2019 (41226)
2018 (31425)
2017 (28294)
2016 (26998)
2015 (31536)
2014 (23727)
2013 (19385)
2012 (20621)
2011 (21641)
2010 (19219)
Location
Africa (750)
Alabama (49)
Alaska (4)
Arizona (147)
Arkansas (13)
Asia (35334)
Australia (7131)
California (5102)
Canada (1815)
China (485)
Colorado (227)
Connecticut (218)
Delaware (133)
Europe (78533)
Florida (809)
Georgia (178)
Idaho (50)
Illinois (465)
India (24)
Indiana (268)
Iowa (8)
Japan (148)
Kansas (94)
Kentucky (19)
Louisiana (9)
Maine (51)
Maryland (797)
Massachusetts (3718)
Michigan (193)
Minnesota (312)
Mississippi (1)
Missouri (78)
Montana (21)
Nebraska (22)
Nevada (56)
New Hampshire (67)
New Jersey (1541)
New Mexico (25)
New York (1508)
North Carolina (806)
North Dakota (6)
Northern California (2241)
Ohio (174)
Oklahoma (5)
Oregon (25)
Pennsylvania (1161)
Puerto Rico (12)
Rhode Island (29)
South America (1030)
South Carolina (19)
South Dakota (1)
Southern California (1963)
Tennessee (82)
Texas (788)
Utah (168)
Virginia (142)
Washington D.C. (50)
Washington State (488)
West Virginia (3)
Wisconsin (41)
568,876 Results for "immutep formerly known as prima biomed".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Immutep Quarterly Activities Report Q3 FY25
April 30, 2025
·
8 min read
Press Releases
Immutep to Participate in Upcoming Investor Conferences
April 2, 2025
·
1 min read
Press Releases
First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
March 26, 2025
·
5 min read
Press Releases
Immutep Quarterly Activities Report Q2 FY25
January 31, 2025
·
10 min read
Business
Immutep Quarterly Activities Report Q3 FY24
Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha (efti) and IMP761 for the quarter ended 31 March 2024 (Q3 FY24).
April 29, 2024
·
7 min read
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Press Releases
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025
March 20, 2025
·
3 min read
Press Releases
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
April 28, 2025
·
2 min read
Drug Development
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024
Immutep Limited today announces encouraging efficacy, safety, and pharmacodynamic data from the safety lead-in of the AIPAC-003 Phase II/III trial presented at the European Society for Medical Oncology (ESMO) Breast Cancer 2024 Congress.
May 15, 2024
·
5 min read
Immutep successfully completes institutional placement and institutional component of entitlement offer
Immutep Limited ACN 009 237 889 is pleased to announce the successful completion of its institutional placement and the institutional component of its 1 for 16 pro rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Immutep.
June 5, 2024
·
7 min read
1 of 56,888
Next
